Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis
- 2 September 2025
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1718-1728
Abstract
Key Points: The prevalence of clonal hematopoiesis in patients with ESKD on hemodialysis was 7%. Clonal hematopoiesis was not associated with stroke, myocardial infarction, or venous thromboembolism. Clonal hematopoiesis was associated with vascular access thrombosis. Background: Patients with ESKD on hemodialysis are at high risk for cardiovascular complications. Clonal hematopoiesis (CH), defined as clonal expansion of hematopoietic stem cells due to acquired mutations, was shown to be associated with cardiovascular events, but this association was not yet assessed in patients with impaired kidney function. Methods: Our aim was to investigate the CH-associated mutation prevalence in patients with ESKD on hemodialysis included in the population-based prospective observational Vienna InVestigation of AtriaL Fibrillation and thromboembolism in hemoDIalysis (VIVALDI) study and to assess an association between CH and cardiovascular outcomes. Peripheral blood DNA samples collected at study inclusion were screened for CH-associated mutations. Results: Five hundred seventy patients were analyzed (median age, 66 years [interquartile range [IQR], 55–75]; 37.1% female). The median follow-up time was 39 months (IQR, 35–41). We detected 44 CH-associated variants in 40 patients (7%), most commonly in the gene DNMT3A (43%), TET2 (18%), and TP53 (18%). Patients with CH were older (75 [IQR, 68–80] versus 65 [IQR, 54–74] years, P < 0.001) and had longer cumulative dialysis time (4 [IQR, 1.0–4.0] versus 2 [IQR, 1.9–5.5] years, P = 0.02). CH was not associated with stroke (subdistribution hazard ratio [SHR], 0.25; 95% confidence interval [CI], 0.04 to 1.84), myocardial infarction (SHR, 0.90; 95% CI, 0.20 to 4.13), three-point major adverse cardiovascular events (SHR, 0.65; 95% CI, 0.33 to 1.28), or venous thromboembolism (SHR, 1.68; 95% CI, 0.35 to 8.12) risk. Patients with CH exhibited a higher risk of vascular access thrombosis (SHR, 2.47; 95% CI, 1.34 to 4.56) and patients with non- DNMT3A CH present with a higher all-cause mortality risk (hazard ratio, 1.71; 95% CI, 1.03 to 2.85). Conclusions: Seven percent of patients with ESKD on hemodialysis presented with CH. There was no association between CH and stroke, myocardial infarction, or venous thromboembolism. CH was associated with vascular access thrombosis.Keywords
Funding Information
- Cardiovascular Cluster of the Medical University of Vienna (Cardiovascular Cluster (CVC) Collaborative Grant)
- Österreichischer Herzfond
This publication has 51 references indexed in Scilit:
- Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1JAMA Cardiology, 2024
- Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular MortalityJACC, 2024
- Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular DiseaseJACC, 2023
- TET2-Driven Clonal Hematopoiesis and Response to CanakinumabJAMA Cardiology, 2022
- A Mendelian randomization study found causal linkage between telomere attrition and chronic kidney diseaseKidney International, 2021
- Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signalingCell Stem Cell, 2021
- Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal HematopoiesisCell Stem Cell, 2018
- Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI)Thrombosis Research, 2017
- Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease StagesSeminars in Nephrology, 2015
- Cardiovascular and Noncardiovascular Mortality Among Patients Starting DialysisJAMA, 2009